Staying on a lower dose of Wegovy: what your options actually are

What the Wegovy dose schedule is actually designed to do

The 0.25 mg starting dose exists for one reason: tolerance. It is not intended to drive weight loss on its own. At that level, most people experience little effect on appetite, the dose is low enough that the body gets used to semaglutide without being hit hard by gastrointestinal side effects from day one. Think of it as an adjustment period rather than active treatment.

From there, the full Wegovy dose schedule moves through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose, typically spending around four weeks at each level. The MHRA approved a dedicated 7.2 mg single-dose pen in April 2026 for adults with a BMI of 30 or above, adding a higher ceiling for those who have already reached 2.4 mg and want to push further under clinical supervision.

None of that is a timetable with penalties for running late. The NHS semaglutide guidance acknowledges that the schedule can be slowed if a patient is not tolerating each step well. Some people spend eight or twelve weeks at 0.5 mg or 1.0 mg before their prescriber is satisfied it is safe to move. That is not a failure. That is the process doing what it is supposed to do.

The key clinical question is whether the current dose is doing enough work at a level you can sustain. Side effects tend to be most noticeable in the first week or two after a dose increase; if they are still disruptive beyond that window, holding at the lower dose is a reasonable short-term decision, and taking a lower dose of Wegovy is something your prescriber can discuss with you in more detail.

When staying on a lower dose makes clinical sense

There are broadly two situations where remaining on a lower Wegovy dose is not just acceptable but sensible. The first is tolerability: if nausea, vomiting, or loose stools are still disrupting daily life several weeks after a dose increase, most prescribers would consider pausing the escalation rather than pressing on. Comfort matters both for quality of life and for adherence, a lower dose you can actually stay on tends to outperform a higher dose you stop taking.

The second situation is when the lower dose is already producing good results. Some people find that 1.0 mg or 1.7 mg produces significant appetite reduction and steady weight loss. If that is the case, there is no clinical imperative to move to 2.4 mg immediately just because the schedule says so. The question of staying on a lower dose of Wegovy long-term is one your prescriber can weigh against your specific response to treatment.

What matters, per NICE's appraisal of semaglutide (TA875), is that patients who have not achieved at least 5% weight loss after six months at their highest tolerated dose should have treatment reviewed. The lower dose is not a problem; insufficient response at the lower dose, with nowhere left to titrate to, is where a review is warranted. You can read the NICE recommendation for semaglutide in full.

Side effects at lower doses, the practical picture

Most of the side effects associated with Wegovy cluster around the gastrointestinal system: nausea is the most commonly reported, followed by diarrhoea, constipation, indigestion, and reflux. These typically peak shortly after a dose increase and settle within a couple of weeks for most people. At the lower end of the dose ladder, they tend to be milder, which is the whole point of starting low.

Keeping the pen in a consistent spot (some people use the fridge door alongside their evening routine as a prompt) can help with weekly adherence, which matters because missing doses disrupts both the tolerability curve and the weight-loss effect. The NHS page on semaglutide has a practical summary of what to watch for and when to contact a prescriber. If you experience severe, persistent stomach pain that spreads to your back, seek medical advice promptly, that is a symptom that needs a clinical assessment rather than a wait-and-see approach.

For storage, Wegovy pens are refrigerated; the Patient Information Leaflet sets out any limited room-temperature window for short periods, and your prescriber or pharmacist can clarify the specifics. Dose-by-dose storage guidance is in the leaflet rather than something to rely on general copy for.

If you are weighing up whether Wegovy suits you versus other options, the treatment overview page sets out what is currently licensed in the UK for weight management, including how tirzepatide compares as an alternative.

Who makes the final call, and how to get that review

Your prescriber does. That applies whether you are asking to slow titration, hold at your current dose, or understand why you have been moved up. The dose schedule is a clinical framework, not a protocol that runs itself.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally (not a triage algorithm) and the same review happens before each repeat order. If your question about lower dosing is live right now, the FAQs page covers some common dose-related queries, and you can reach the team directly via the contact page. More detail on how the Wegovy dose schedule works in clinical practice is covered in the Wegovy dosing guide.

The cost of treatment at different dose stages is a separate question, if that is on your mind, the Wegovy cost guide addresses what private pricing actually reflects and what to look out for. Starting with a free consultation through our treatment page is the practical next step if you want a prescriber's view on where you are in the process.